Viatris: A US Healthcare Company Worldwide

Hey, this is Stocks_Pedia.

I would like to introduce some unfamiliar companies that may be of some help to your investments.

The company I'm going to introduce is $Viatris Inc.(VTRS)$.

It went public in 2020.

[Company Profile]

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).

The company offers drugs in various therapeutic areas, medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs.

The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.

Viatris Inc. was founded in 2020 and is headquartered in Canonsburg, Pennsylvania.

[History & Events]

2020: Viatris was found by Upjohn, which merged with Mylan in a Reverse Morris Trust transaction.

2020: The company began trading on the NASDAQ using the ticker symbol VTRS following the combination.

2020: The company announced a cost-reducing restructuring plan which would impact up to 20% of its global workforce, or 9,000 jobs at its facilities around the world.

2020: The company worked with Sesame Workshop to create resources to help children and their caregivers manage their social and emotional needs impacted by the COVID-19 pandemic.

2021: Viatris was ranked 5th by Fortune on its annual "Change the World" list.

2021: Viatris partnered with the American College of Cardiology, the NCD Alliance, and the World Heart Federation to create the NCD Academy, a platform to help fight non-communicable diseases around the world.

2021: The company partnered with Atomo Diagnostics and Unitaid to expand access to HIV self-testing to 135 countries and lower the price of the tests by around 50%.

2022: Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics.

[Main Business Segments]

Source: TigerTrade

[Net Income & Total Revenue]

Source: TigerTrade

Source: TigerTrade

[Competitors]

$Amgen(AMGN)$

$Sanofi(SNYNF)$

$Teva Pharmaceutical(TEVA)$

$Astellas Pharma, Inc.(ALPMF)$